- Home
- IGIC vs ORKA Comparison
IGIC vs ORKA Comparison
Compare IGIC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGIC
- ORKA
- Stock Information
- Founded
- IGIC 2001
- ORKA 2004
- Country
- IGIC Jordan
- ORKA United States
- Employees
- IGIC N/A
- ORKA N/A
- Industry
- IGIC Property-Casualty Insurers
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IGIC Finance
- ORKA Health Care
- Exchange
- IGIC Nasdaq
- ORKA Nasdaq
- Market Cap
- IGIC 1.0B
- ORKA 1.2B
- IPO Year
- IGIC N/A
- ORKA N/A
- Fundamental
- Price
- IGIC $22.20
- ORKA $27.97
- Analyst Decision
- IGIC Buy
- ORKA Strong Buy
- Analyst Count
- IGIC 2
- ORKA 7
- Target Price
- IGIC $31.50
- ORKA $42.86
- AVG Volume (30 Days)
- IGIC 62.5K
- ORKA 517.8K
- Earning Date
- IGIC 11-04-2025
- ORKA 11-12-2025
- Dividend Yield
- IGIC 4.72%
- ORKA N/A
- EPS Growth
- IGIC 11.00
- ORKA N/A
- EPS
- IGIC 2.79
- ORKA N/A
- Revenue
- IGIC $535,109,000.00
- ORKA N/A
- Revenue This Year
- IGIC $6.05
- ORKA N/A
- Revenue Next Year
- IGIC $7.01
- ORKA N/A
- P/E Ratio
- IGIC $7.97
- ORKA N/A
- Revenue Growth
- IGIC 9.99
- ORKA N/A
- 52 Week Low
- IGIC $19.04
- ORKA $5.49
- 52 Week High
- IGIC $27.76
- ORKA $30.51
- Technical
- Relative Strength Index (RSI)
- IGIC 38.66
- ORKA 73.85
- Support Level
- IGIC $22.03
- ORKA $25.11
- Resistance Level
- IGIC $22.61
- ORKA $27.75
- Average True Range (ATR)
- IGIC 0.45
- ORKA 2.09
- MACD
- IGIC -0.01
- ORKA -0.00
- Stochastic Oscillator
- IGIC 19.72
- ORKA 86.26
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.